Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 6

A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications

Authors Behzad Molavi, Negah Rassouli, Suveer Bagwe, Neda Rasouli

Published Date January 2007 Volume 2007:3(6) Pages 967—973

DOI

Published 15 January 2007

Behzad Molavi1, Negah Rassouli2, Suveer Bagwe1, Neda Rasouli2

Central Arkansas Veterans Healthcare System and University of Arkansas for Medical sciences, 1Division of cardiology and 2Division of Endocrinology, College of Medicine, Little Rock, Arkansas, USA

Abstract: The rising incidence of obesity and insulin resistance to epidemic proportions has closely paralleled the surge in the prevalence of diabetes and outpaced therapeutic advances in diabetes prevention and treatment. Current evidence points to obesity induced oxidative stress and chronic inflammation as the common denominators in the evolution of insulin resistance and diabetes. Of all the hypoglycemic agents in the pharmacological arsenal against diabetes, thiazolidinediones, in particular pioglitazone, as well as metformin appear to have additional effects in ameliorating oxidative stress and inflammation; rendering them attractive tools for prevention of insulin resistance and diabetes. In addition to their hypoglycemic and lipid modifying properties, pioglitazone and metformin have been shown to exert anti-oxidative and anti-inflammatory effects in vascular beds, potentially slowing the accelerated atherosclerosis in diabetes, which is the major cause of morbidity and mortality in the affected population. The combination of pioglitazone and metformin would thus appear to be an effective pharmacological intervention in prevention and treatment of diabetes. Finally, this review will address the currently available evidence on diabetic cardiomyopathy and the potential role of combination therapy with pioglitazone and metformin.

Keywords: insulin resistance, oxidative stress, inflammation, pioglitazone, metformin, atherosclerosis, diabetic cardiomyopathy

Download Article [PDF] 

Readers of this article also read:

Emerging roles for antiangiogenesis factors in management of ocular disease

Saeed MU, Gkaragkani E, Ali K

Clinical Ophthalmology 2013, 7:533-543

Published Date: 13 March 2013

Writing 3D patterns of microvessels

Juodkazis S

International Journal of Nanomedicine 2012, 7:3701-3702

Published Date: 13 July 2012

Corrigendum

Sailasuta N, Harris K, Tran T, Ross B

Neuropsychiatric Disease and Treatment 2011, 7:707-708

Published Date: 25 November 2011

Erratum

RA Kurt, K Gündüz

Clinical Ophthalmology 2010, 4:981-982

Published Date: 6 September 2010

Potential bias in ophthalmic pharmaceutical clinical trials

Paul Varner

Clinical Ophthalmology 2008, 2:401-411

Published Date: 30 June 2008

Fifty years chlorpromazine: a historical perspective

Thomas A Ban

Neuropsychiatric Disease and Treatment 2007, 3:495-500

Published Date: 8 October 2007

Short-term effect of the HMG-CoA reductase inhibitor rosuvastatin on erythrocyte nitric oxide synthase activity

Barbara Ludolph, Wilhelm Bloch, Malte Kelm, Rainer Schulz, Petra Kleinbongard

Vascular Health and Risk Management 2007, 3:1069-1073

Published Date: 15 January 2007

Management of cancer-associated venous thrombosis

Ozlem Er, Leo Zacharski

Vascular Health and Risk Management 2006, 2:351-356

Published Date: 1 March 2006